New Cancer Drug Hope

AstraZeneca has been collaborating with researchers who detected a potential Aurora B inhibitor.

Photo: New Cancer Drug Hope

A scientific paper, published in 2003 highlighted the potential success of targeting Aurora B, in the hope of developing a new class of drugs to inhibit this enzyme.
Aurora A and B are a type of enzyme known as protein kinases; they modify other proteins by chemically adding phosphate groups to them. In cancer, both these protein kinases are ‘over-expressed’.
At the Faculty of Life Sciences, University of Manchester, researchers have been studying a chemical that blocks, or inhibits, the catalytic actions of Aurora B and it has effectively killed cancer cells in lab grown cultures. ‘The first compounds were designed to inhibit a related enzyme called Aurora A,’ said Dr Stephen Taylor, who leads the research team. ‘Our research has shown that inhibiting Aurora B is a far more successful method of killing cancer cells. We’ve been strongly encouraged by these latest results.’

The research - published in the Journal of Cell Science - will be of interest to many other scientists looking at Aurora inhibitors (currently over 10 companies are involved in Aurora cancer research).
Although effective, many current cancer drugs are toxic. However, early clinical trials of Aurora-B drug’s toxicity have shown mild but not major adverse effects to patients. The next stage of trials to test its effectiveness is likely to begin soon.
The first results from the Phase I clinical trials using Aurora inhibitors were presented at the American Society for Clinical Oncology conference in Atlanta, in June

14.11.2006

Read all latest stories

Related articles

Photo

Oncology early detection tool

Blood test for 50+ types of cancer promising for screening

Final results from a study of a blood test that can detect more than 50 types of cancer have shown that it is accurate enough to be rolled out as a multi-cancer screening test among people at higher…

Photo

Alcohol ups colon cancer risk

Denmark - Regular drinkers significantly increase their risk of rectal cancer, but that risk is reduced if wine makes up a third or more of weekly consumption, according to research carried out by…

Photo

ECCO 15 and 34th ESMO Multidisciplinary Congress unites European Oncology

The first joint congress ECCO 15 - ESMO 34 of the European CanCer Organisation (ECCO) and the European Society for Medical Oncology (ESMO) is taking place this week in Berlin. It is the only…

Related products

Creative Biosciences - Colosafe

Creative Biosciences - Colosafe

Creative Biosciences (Guangzhou) Co., Ltd.
Alsachim, a Shimadzu group company – Dosinaco

Clinical Chemistry

Alsachim, a Shimadzu group company – Dosinaco

Alsachim, a Shimadzu Group Company
ASP Lab Automation – Recapper KapSafe

Sample Processing

ASP Lab Automation – Recapper KapSafe

ASP Lab Automation AG
ASP Lab Automation – Tube Sorter SortPro

Sample Processing

ASP Lab Automation – Tube Sorter SortPro

ASP Lab Automation AG
Beckman Coulter – Access Interleukin-6 (IL-6)

Immunoassays

Beckman Coulter – Access Interleukin-6 (IL-6)

Beckman Coulter, Inc.
Beckman Coulter – DxA 5000

Sample Processing

Beckman Coulter – DxA 5000

Beckman Coulter, Inc.
Subscribe to Newsletter